{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:48:38Z","timestamp":1790621318686,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T00:00:00Z","timestamp":1450828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s11892-015-0693-3","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T07:54:29Z","timestamp":1450857269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["GLP-1 and Amylin in the Treatment of Obesity"],"prefix":"10.1007","volume":"16","author":[{"given":"T.","family":"Jorsal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rungby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,23]]},"reference":[{"key":"693_CR1","unstructured":"World Health Organization. Obesity and overweight. 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/ ."},{"key":"693_CR2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2213-8587(13)70218-3","volume":"2","author":"S Madsbad","year":"2014","unstructured":"Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol Elsevier Ltd. 2014;2:152\u201364.","journal-title":"Lancet Diabetes Endocrinol. Elsevier Ltd"},{"key":"693_CR3","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1007\/s00125-012-2556-7","volume":"55","author":"C Dirksen","year":"2012","unstructured":"Dirksen C, J\u00f8rgensen NB, Bojsen-M\u00f8ller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia. 2012;55:1890\u2013901.","journal-title":"Diabetologia."},{"key":"693_CR4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2213-8587(13)70158-X","volume":"2","author":"AD Miras","year":"2014","unstructured":"Miras AD, le Roux CW. Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. Lancet Diabetes Endocrinol Elsevier Ltd. 2014;2:141\u201351.","journal-title":"Lancet Diabetes Endocrinol. Elsevier Ltd"},{"key":"693_CR5","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Barquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4223\u20136. This study provides novel findings indicating that the GLP-1R found in key neuronal pathways of the brain that regulate energy balance likely mediates liraglutide-induced weight loss.","journal-title":"J. Clin. Invest."},{"key":"693_CR6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","volume":"26","author":"P Hollander","year":"2003","unstructured":"Hollander P, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26:784\u201390.","journal-title":"Diabetes Care."},{"key":"693_CR7","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","volume":"48","author":"I Chapman","year":"2005","unstructured":"Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48:838\u201348.","journal-title":"Diabetologia."},{"key":"693_CR8","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet Elsevier Ltd. 2009;374:1606\u201316.","journal-title":"Lancet. Elsevier Ltd"},{"key":"693_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrendo.2013.47","volume":"9","author":"SA Sadry","year":"2013","unstructured":"Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol Nature Publishing Group. 2013;9:425\u201333.","journal-title":"Nat. Rev. Endocrinol. Nature Publishing Group"},{"key":"693_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diabetes.53.suppl_3.S233","volume":"53","author":"O Schmitz","year":"2004","unstructured":"Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004;53:233\u20138.","journal-title":"Diabetes."},{"key":"693_CR11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1152\/ajpregu.00275.2010","volume":"299","author":"NT Bello","year":"2010","unstructured":"Bello NT, Kemm MH, Ofeldt EM, et al. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Regul Integr Comp Physiol. 2010;299:945\u201352.","journal-title":"Am. J. Physiol. Regul. Integr. Comp Physiol"},{"key":"693_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","volume":"5","author":"RJ Rodgers","year":"2012","unstructured":"Rodgers RJ, Tschop MH, Wilding JPH. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5:621\u20136.","journal-title":"Dis. Model. Mech."},{"key":"693_CR13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today Elsevier Ltd. 2015;20:122\u20138. This paper gives a fine overview of the current status and potentials ahead in development of peptide pharmaceuticals.","journal-title":"Drug Discov. Today. Elsevier Ltd"},{"key":"693_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0078154","volume":"8","author":"JL Trevaskis","year":"2013","unstructured":"Trevaskis JL, Mack CM, Sun C, et al. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLoS One. 2013;8:1\u201312.","journal-title":"PLoS One."},{"key":"693_CR15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2337\/diacare.29.02.06.dc05-1267","volume":"29","author":"MC Riddle","year":"2006","unstructured":"Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435\u201349.","journal-title":"Diabetes Care."},{"key":"693_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.physbeh.2006.04.001","volume":"89","author":"TA Lutz","year":"2006","unstructured":"Lutz TA. Amylinergic control of food intake. Physiol Behav. 2006;89:465\u201371.","journal-title":"Physiol. Behav."},{"key":"693_CR17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1152\/ajpendo.2000.278.3.E484","volume":"278","author":"CB Juhl","year":"2000","unstructured":"Juhl CB, P\u00f8rksen N, Sturis J, et al. High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab. 2000;278:484\u201390.","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"693_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1463-1326.2012.01670.x","volume":"15","author":"TA Lutz","year":"2013","unstructured":"Lutz TA. The interaction of amylin with other hormones in the control of eating. Diabetes, Obes Metab. 2013;15:99\u2013111.","journal-title":"Diabetes, Obes Metab"},{"key":"693_CR19","first-page":"1060","volume":"32","author":"T Qi","year":"2011","unstructured":"Qi T, Ly K, Poyner DR, et al. Structure-function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors. Peptides Elsevier Inc. 2011;32:1060\u20137.","journal-title":"Peptides. Elsevier Inc"},{"key":"693_CR20","doi-asserted-by":"crossref","unstructured":"Just R, Simms J, Furness SGB, Christopoulos A SA. Understanding Amylin Receptors. Springer; 2010","DOI":"10.1007\/978-90-481-2909-6_3"},{"key":"693_CR21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MED.0b013e32835b896f","volume":"20","author":"JD Roth","year":"2013","unstructured":"Roth JD. Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology. Curr Opin Endocrinol Diabetes Obes. 2013;20:8\u201313.","journal-title":"Curr. Opin. Endocrinol. Diabetes. Obes."},{"key":"693_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.physbeh.2013.02.006","volume":"112\u2013113","author":"D Z\u00fcger","year":"2013","unstructured":"Z\u00fcger D, Forster K, Lutz TA, et al. Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli. Physiol Behav Elsevier Inc. 2013;112\u2013113:61\u20139.","journal-title":"Physiol. Behav. Elsevier Inc"},{"key":"693_CR23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1476-5381.2011.01537.x","volume":"166","author":"JD Roth","year":"2012","unstructured":"Roth JD, Erickson MR, Chen S, et al. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms. Br J Pharmacol. 2012;166:121\u201336.","journal-title":"Br. J. Pharmacol."},{"key":"693_CR24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc10-0518","volume":"34","author":"HS Moon","year":"2011","unstructured":"Moon HS, Chamberland JP, Diakopoulos KN, et al. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes Care. 2011;34:132\u20138.","journal-title":"Diabetes Care."},{"key":"693_CR25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-011-2332-0","volume":"55","author":"HS Moon","year":"2012","unstructured":"Moon HS, Chamberland JP, Mantzoros CS. Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C 2C 12 muscle and AML12 liver cell lines. Diabetologia. 2012;55:215\u201325.","journal-title":"Diabetologia."},{"key":"693_CR26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00125-004-1342-6","volume":"47","author":"T Vilsb\u00f8ll","year":"2004","unstructured":"Vilsb\u00f8ll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004;47:357\u201366.","journal-title":"Diabetologia."},{"key":"693_CR27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0016-5085(83)80080-8","volume":"85","author":"K Sj\u00f6lund","year":"1983","unstructured":"Sj\u00f6lund K, Sand\u00e9n G, H\u00e5kanson R. Endocrine cells in human intestine: an immunocytochemical study. Gastroent. 1983;85:1120\u201330.","journal-title":"Gastroent."},{"key":"693_CR28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409\u201339.","journal-title":"Physiol. Rev."},{"key":"693_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","volume":"114","author":"T Vilsb\u00f8ll","year":"2003","unstructured":"Vilsb\u00f8ll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114:115\u201321.","journal-title":"Regul. Pept."},{"key":"693_CR30","first-page":"1","volume":"1","author":"S Madsbad","year":"2013","unstructured":"Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab. 2013;1:1\u201313.","journal-title":"Diabetes Obes Metab"},{"key":"693_CR31","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280\u201390.","journal-title":"Endocrinology."},{"key":"693_CR32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2337\/diabetes.48.5.1045","volume":"48","author":"H Sandhu","year":"1999","unstructured":"Sandhu H, Wiesenthal SR, MacDonald PE, et al. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes. 1999;48:1045\u201353.","journal-title":"Diabetes."},{"key":"693_CR33","first-page":"31","volume":"137","author":"P Bullock","year":"2015","unstructured":"Bullock P, Scott R. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 2015;137:31\u20133.","journal-title":"Endocrinology."},{"key":"693_CR34","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1210\/endo.135.5.7956929","volume":"135","author":"M Egan","year":"2007","unstructured":"Egan M, Bernier M. Glucagon-like peptide-1 (7\u201334) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology. 2007;135:2070\u20135.","journal-title":"Endocrinology."},{"key":"693_CR35","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"EE Mulvihill","year":"2014","unstructured":"Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35:992\u20131019.","journal-title":"Endocr. Rev."},{"key":"693_CR36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00125-005-1705-7","volume":"48","author":"JJ Holst","year":"2005","unstructured":"Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48:612\u20135.","journal-title":"Diabetologia."},{"key":"693_CR37","first-page":"1831","volume":"75","author":"MC Jones","year":"2007","unstructured":"Jones MC. Therapies for diabetes: pramlintide and exenatide. Am Fam Physician. 2007;75:1831\u20135.","journal-title":"Am. Fam. Physician."},{"key":"693_CR38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","volume":"26","author":"P Hollander","year":"2003","unstructured":"Hollander P, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26:784\u201390.","journal-title":"Diabetes Care."},{"key":"693_CR39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","volume":"5","author":"P Hollander","year":"2003","unstructured":"Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes, Obes Metab. 2003;5:408\u201314.","journal-title":"Diabetes, Obes Metab"},{"key":"693_CR40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","volume":"12","author":"P Hollander","year":"2004","unstructured":"Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12:661\u20138.","journal-title":"Obes. Res."},{"key":"693_CR41","first-page":"1816","volume":"31","author":"S Smith","year":"2008","unstructured":"Smith S, Aronne L, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Biomed Res. 2008;31:1816\u201323.","journal-title":"Biomed. Res."},{"key":"693_CR42","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-015-3608-6","volume":"58","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? Diabetologia. 2015;58:1745\u201350.","journal-title":"Diabetologia."},{"key":"693_CR43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejim.2014.03.005","volume":"25","author":"A Lund","year":"2014","unstructured":"Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25:407\u201314.","journal-title":"Eur J Intern Med."},{"key":"693_CR44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2337\/dc11-s231","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34:279\u201384.","journal-title":"Diabetes Care."},{"key":"693_CR45","first-page":"1","volume":"344","author":"T Vilsboll","year":"2012","unstructured":"Vilsboll T, Christensen M, Junker A, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:1\u201311.","journal-title":"BMJ."},{"issue":"3","key":"693_CR46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2009.05.1998","volume":"121","author":"J McGill","year":"2013","unstructured":"McGill J. Insights from the liraglutide clinical development program-the liraglutide effect and action in diabetes (LEAD) studies. Postgr Med. 2013;121(3):16\u201325.","journal-title":"Postgr. Med."},{"key":"693_CR47","first-page":"18","volume":"58","author":"BK Sethi","year":"2010","unstructured":"Sethi BK, Viswanathan V, Kumar A, et al. Liraglutide in clinical practice: insights from LEAD programme. J Assoc Physicians India. 2010;58:18\u201322.","journal-title":"J. Assoc. Physicians India."},{"issue":"6","key":"693_CR48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Harper A, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843\u201354.","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"693_CR49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. Jama. 2015;314(7):687\u201399.","journal-title":"Jama"},{"key":"693_CR50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322. This study provides important clinical data on liraglutide 3.0 mg recently approved for treatment of obesity.","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"693_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.2015.975205","volume":"14","author":"T Chalmer","year":"2015","unstructured":"Chalmer T, Almdal TP, Vilsb\u00f8ll T, et al. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes\u2014focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf. 2015;14(1):1\u201310.","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl1","key":"693_CR52","first-page":"S38","volume":"57","author":"R DeFronzo","year":"2014","unstructured":"DeFronzo R, Bergenstal R, Bode B, et al. Effect of liraglutide 3.0 mg cessation on efficacy and safety\/tolerability after 56 weeks\u2019 treatment in obese\/overweight adults with type 2 diabetes: SCALE diabetes. Diabetologia. 2014;57(Suppl1):S38\u20139.","journal-title":"Diabetologia"},{"key":"693_CR53","unstructured":"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm427913.htm U.S. Food and Drug Administration. FDA approves weight-management drug Saxenda. 2014."},{"key":"693_CR54","unstructured":"European Medicines Agency, Saxenda recommended for approval in weight management in adults. 2015 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/01\/news_detail_002255.jsp&mid=WC0b01ac058004d5c1 ."},{"key":"693_CR55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-nutr-071812-161201","volume":"34","author":"MR Hayes","year":"2014","unstructured":"Hayes MR, Mietlicki-Baase EG, Kanoski SE, et al. Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu Rev Nutr. 2014;34:237\u201360.","journal-title":"Annu. Rev. Nutr."},{"key":"693_CR56","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1146\/annurev.biochem.69.1.923","volume":"69","author":"PE Dawson","year":"2000","unstructured":"Dawson PE, Kent SBH. Synthesis of native proteins by chemical ligation. Annu Rev Biochem. 2000;69:923\u201360.","journal-title":"Annu. Rev. Biochem."},{"key":"693_CR57","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","volume":"58","author":"A Pocai","year":"2009","unstructured":"Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1\/glucagon receptor agonism reverses obesity in mice. Diabetes. 2009;58:2258\u201366.","journal-title":"Diabetes."},{"key":"693_CR58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1677\/JOE-06-0018","volume":"192","author":"TH Claus","year":"2007","unstructured":"Claus TH, Pan CQ, Buxton JM, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J Endocrinol. 2007;192:371\u201380.","journal-title":"J. Endocrinol."},{"key":"693_CR59","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1463-1326.2012.01676.x","volume":"15","author":"K Fosgerau","year":"2013","unstructured":"Fosgerau K, Jessen L, Lind TJ, et al. The novel GLP-1-gastrin dual agonist, ZP3022, increases \u03b2-cell mass and prevents diabetes in db\/db mice. Diabetes, Obes Metab. 2013;15:62\u201371.","journal-title":"Diabetes, Obes Metab"},{"key":"693_CR60","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.2337\/db14-1-388","volume":"63","author":"R Just","year":"2014","unstructured":"Just R. The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice. Diabetes. 2014;63:A1\u2013A102.","journal-title":"Diabetes"},{"key":"693_CR61","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","volume":"5","author":"B Finan","year":"2013","unstructured":"Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5:209ra151.","journal-title":"Sci. Transl. Med."},{"key":"693_CR62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/JOE-12-0368","volume":"215","author":"A Pocai","year":"2012","unstructured":"Pocai A. Unraveling oxyntomodulin, GLP1\u2019s enigmatic brother. J Endocrinol. 2012;215:335\u201346.","journal-title":"J. Endocrinol."},{"key":"693_CR63","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1007\/s11095-010-0341-1","volume":"28","author":"RF Witkamp","year":"2011","unstructured":"Witkamp RF. Current and future drug targets in weight management. Pharm Res. 2011;28:1792\u2013818.","journal-title":"Pharm. Res."}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-015-0693-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-015-0693-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-015-0693-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T04:47:04Z","timestamp":1599972424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-015-0693-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,23]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1007\/s11892-015-0693-3","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,23]]},"article-number":"1"}}